TEVA May 2024 14.000 put
| Previous close | 1.1400 |
| Open | 0.6300 |
| Bid | 0.6600 |
| Ask | 0.7200 |
| Strike | 14.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.6200 - 0.6700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.86k |
- Reuters
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
The U.S. Supreme Court on Monday declined to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz that were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling by the patent-focused U.S. Court of Appeals for the Federal Circuit against the company, which in 2018 had sued Teva and Apotex in Delaware for patent infringement after they applied to make generic versions of Vanda's Hetlioz, a circadian-rhythm drug used to treat rare sleep disorders.
Insider Monkey11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Best Low Price Pharma […]
ZacksZacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Teva, Dr. Reddy's and Viatris have been highlighted in this Industry Outlook article.
